Australia's most trusted
source of pharma news
Posted 17 February 2026 PM
Ternarx has secured “significant investment” to create a US-based spin-off company, Ternarx Bio, to advance its lead program in prostate cancer.
It marks less than two years since Health Minister, Mark Butler, announced the official launch of Ternarx, a WEHI spin-out company borne from the Australian Centre for Targeted Therapeutics (ACTT) in Bundoora, which received a $15 million grant from the Australian government’s Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative in October 2023.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.